Previous 10 | Next 10 |
home / stock / vphif / vphif news
Mr. Steve Saviuk reports VALEO PHARMA INC. ENTERS INTO AN AGREEMENT FOR ENERZAIR BREEZHALER AND ATECTURA BREEZHALER IN CANADA Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF) (FSE: VP2) ("Valeo" or the "Company") has entered into a commercialization and supply agreement with ...
Valeo Pharma ([[VPHIF]]) announces that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals for the Canadian commercialization of two asthma therapies, Enerzair Breezhaler and Atectura Breezhaler.Under the Agreement, Valeo will be res...
Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada Canada NewsWire Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative ...
Valeo Pharma to Report First Quarter 2021 Results and Hold Investors Conference Call / Webcast Canada NewsWire MONTREAL , March 26, 2021 /CNW Telbec/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian ...
Valeo Pharma (VPHIF): Q4 Net loss of $1.2M.Revenue of $2.2M (+69.2% Y/Y)Press Release For further details see: Valeo Pharma reports Q4 results
Valeo Pharma Reports its 2020 Fourth Quarter and Year-End Results and Highlights Canada NewsWire Q4-20 net revenues of $2.2 million , up 76 % vs Q4-19, 2020 net revenues of $7.5 million up 14% vs 2019 Hiring of Frederic Fasano as new Presi...
Valeo Pharma to Report Fourth Quarter and 2020 Year-End Results and Hold Investors Conference Call / Webcast Canada NewsWire MONTREAL , Feb. 19, 2021 /CNW Telbec/ - Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company ")...
Valeo Pharma's Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial Canada NewsWire Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to re...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – February 3, 2021 – With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size ...
The health crisis has completely changed life as we know it and caused a significant shift in consumer demand for immune-boosting products, vitamins, and supplements. Now, due to growing awareness around heath, the wellness supplements market is projected to reach $386.29 bill...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...